Management of metastatic renal cell carcinoma in patients with poor prognosis
Andrea Bullock, David F McDermott, Michael B AtkinsDivision of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USAAbstract: An improved understanding of renal cell carcinoma (RCC) biology has translated into major advances in the treatment of patients with metastatic RCC in re...
Main Authors: | Andrea Bullock, David F McDermott, Michael B Atkins |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2010-05-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/management-of-metastatic-renal-cell-carcinoma-in-patients-with-poor-pr-a4485 |
Similar Items
-
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma
by: Matthew Weinstock, et al.
Published: (2015-12-01) -
Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
by: Lana Hamieh, et al.
Published: (2018-09-01) -
Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma
by: Haijian Zhang, et al.
Published: (2017-02-01) -
Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients
by: Romualdo Barroso-Sousa, et al.
Published: (2014-12-01) -
Cancer associated macrophage-like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time
by: Amama Ali, et al.
Published: (2023-06-01)